John F. DiPersio, MD, PhD [Chair] ('13)
Ivo Paul Touw, PhD [Vice Chair] ('13)
Alan B. Cantor, MD, PhD (’13)
Kent W. Christopherson II, PhD ('14)
Jason E. Farrar, MD ('14)
Ian Hitchcock, PhD (’13)
Jane L. Liesveld, MD ('15)
Lalitha Nagarajan, PhD ('14)
Jing Zhang, PhD ('16)
Yi Zheng, PhD ('16)
The Scientific Committee on Hematopoiesis focuses on the areas related to cytokines, cytokine receptors and downstream signaling pathways including transcription factors, in the context of normal and pathological hematological processes. It covers a wide range of clinical areas including malignant and non-malignant hematological diseases. Although there may be significant overlap with other scientific committees our charge will be to focus on the fundamental biology and genetics of normal and dysregulated blood cell production and to highlight specific genes, proteins or signaling pathways that are altered in bone marrow failure states, stem cell proliferation states, and in states of leukemic transformation.
The areas of focus by the Scientific Committee on Hematopoiesis include but are not limited to: clinical aspects (diagnosis and treatment) of myeloid, erythroid, and megakaryocytic/platelet disorders. In addition, this committee will focus on pathways of cytokine and chemokine signaling, the roles of various transcription factors in normal and malignant hematopoiesis, developmental pathways critical for undifferenated stem cell and lineage-specific progenitor development, stem cell quiescence, stem cell survival and pathways and genes involved in altered hematopoietic development/differentiation.The committee will also focus on pathways involved in inflammation and pathways linking inflammation with tumor/leukemia progression and emerging methodologies that are both innovative and informative of basic pathways critical for both normal and malignant hematopoiesis.
Finally we will focus on comprehensive and state-of-the-art analyses of genes and expression of genes (expression arrays and RNAseq) essential for normal stem cell and linage-specific stem cell development, somatic mutations and structural variants associated with pre-malignant and malignant hematologic diseases and inherited normal variants that may contribute to the development of disorders of hematopoiesis.
back to top